rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SPRC
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      SciSparc appoints former Israeli security advisor to AI board
      Nov 16Investing.comSPRC
      SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company’s SAB
      Nov 16Yahoo FinanceSPRC
      SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications By FinanceWire
      Oct 26Investing.comSPRC
      12 Health Care Stocks Moving In Monday's Pre-Market Session
      Oct 26BenzingaSPRCXNCR
      SciSparc subsidiary completes drug manufacturing for trial
      Oct 22Investing.comSPRC
      SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
      Oct 22Yahoo FinanceSPRC
      SciSparc shifts strategic focus to agentic AI technologies
      Oct 19Investing.comSPRC
      Why Is SciSparc Stock Gaining Thursday?
      Oct 15BenzingaSPRC
      12 Health Care Stocks Moving In Thursday's Pre-Market Session
      Oct 15BenzingaSPRC
      Why is Scisparc stock surging today?
      Oct 15Investing.comSPRC
      SciSparc shifts strategic focus to agentic AI technologies
      Oct 15Investing.comSPRC
      SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
      Oct 15Yahoo FinanceSPRC
      SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture
      Oct 7Yahoo FinanceSPRC
      SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

      The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developi

      Sep 23Yahoo FinanceSPRC
      SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

      This Strategic Engagement is Designed to Strengthen NeuroThera's U.S. Market Position, Visibility Among Key U.S. Federal Stakeholders, Reinforce the Clinical and PublicHealth Importance of Advancing New Treatment Options for Adult Tourette Syndrome T...

      Sep 2Yahoo FinanceSPRC
      SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

      TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Lab...

      Aug 31Business InsiderSPRC
      SciSparc appoints AI professor to advisory board
      Aug 26Investing.comSPRC
      SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

      The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market TEL AVIV, Israel, Aug. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced the addition of Prof. Carmel Domshlak, an internationally recognized artificial intelligence (“AI”) expert and professor at the Technion – Israel Institute of Technology (“Technion”), to the Company’s n

      Aug 26Yahoo FinanceSPRC
      SciSparc subsidiary publishes MDMA combination patent application
      Aug 24Investing.comSPRC
      SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

      U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA TEL AVIV, Israel, Aug. 24, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company

      Aug 24Yahoo FinanceCMNDSPRC

      This is the newest page. Registered accounts read further back.